文献速递膀胱癌与上尿路尿路上皮癌

Cxbladder Triage Plus在澳大利亚血尿患者中的验证:AUSSIE研究

Validation of Cxbladder Triage Plus in Australian patients with haematuria: the AUSSIE study.
PubMed 文献 · BJU Int · 2026-10-18

AUSSIE研究为多中心前瞻性观察研究,纳入691例有可见或非可见血尿且无尿路上皮癌史的成人,在膀胱镜前检测Cxbladder Triage Plus。该检测敏感性89%、特异性79%、阴性预测值99%,阴性率74%,仅6例肿瘤未检出。

要点

  • Cxbladder Triage Plus对尿路上皮癌敏感性89%、阴性预测值99%。
  • 该检测阴性率74%,可辅助风险分层减少不必要的膀胱镜。
  • 与2025 AUA风险分层标准相比,阳性预测值提高3.3倍。

核心结论

  • Cxbladder Triage Plus在澳大利亚常规实践中对可见或非可见血尿患者的尿路上皮癌风险分层具有临床验证价值。

研究设计与样本

  • 多中心前瞻性观察研究(AUSSIE),纳入691例年龄≥18岁、有可见或非可见血尿、无尿路上皮癌史且转诊膀胱镜的成人,于2023年9月至2025年8月在澳大利亚四个临床中心入组。

主要发现

  • 691例可评估样本中54例(7.8%)经组织病理确诊肿瘤,其中可见血尿44例、非可见血尿10例。
  • 与膀胱镜相比,Cxbladder Triage Plus敏感性89%、特异性79%、阳性预测值27%、阴性预测值99%、阴性率74%。
  • 6例肿瘤未检出,包括5例低级别Ta和1例T3b脐尿管腺癌。
  • 与2025年美国泌尿外科协会风险分层标准相比,Cxbladder Triage Plus阳性预测值提高3.3倍。

临床怎么用

  • 对于无尿路上皮癌史的可见或非可见血尿患者,可在膀胱镜前使用Cxbladder Triage Plus进行风险分层,高阴性预测值有助于识别可能免于侵入性检查的低风险患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To assess the clinical validity of Cxbladder Triage Plus (Pacific Edge Ltd., Dunedin, New Zealand), a non-invasive urinary biomarker assay, for urothelial carcinoma (UC) risk stratification compared with standard-of-care evaluation (cystoscopy) in patients presenting with visible or non-visible haematuria (VH or NVH) in routine practice in Australia. PATIENTS AND METHODS: A multicentre, prospective, observational study (AUSSIE; Australian and New Zealand Clinical Trial Registry identifier: ACTRN12622001127796) enrolled adults (aged ≥18 years) presenting with VH or NVH, no UC history and a cystoscopy referral between September 2023 and August 2025 across four Australian clinical sites. Midstream urine samples were tested with Cxbladder Triage Plus prior to cystoscopy. The primary outcome was diagnostic performance of Cxbladder Triage Plus (sensitivity, specificity, positive predictive value [PPV], negative PV [NPV], and test-negative rate [TNR]) vs white light cystoscopy and histopathological UC confirmation. RESULTS: Of 691 patients with evaluable samples (424 with VH, 267 with NVH), 54 (7.8%) had histopathology-confirmed tumours (44 with VH, 10 with NVH). Compared with cystoscopy, Cxbladder Triage Plus had sensitivity of 89%, specificity 79%, PPV 27%, NPV 99%, and TNR 74%. Six tumours were not detected (five low-grade Ta, one T3b urachal adenocarcinoma). Compared with 2025 American Urological Association risk stratification criteria, Cxbladder Triage Plus provided a 3.3-fold increase in PPV. CONCLUSION: These findings provide clinical validation of Cxbladder Triage Plus for UC risk stratification in Australian patients presenting with VH or NVH in routine clinical practice.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Buhariwalla V, Sethi K, Vela I, et al. Validation of Cxbladder Triage Plus in Australian patients with haematuria: the AUSSIE study. BJU Int. 2026. PMID: 42893815. doi:10.1111/bju.70504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。